Literature DB >> 24780454

Natural history and clinical characteristics of CKD in type 1 and type 2 diabetes mellitus.

Sally M Marshall1.   

Abstract

The nature of CKD in diabetes is changing. Diabetic glomerulosclerosis remains the cause of CKD in most type 1 diabetic individuals. However, the rate of progression of diabetic nephropathy has slowed because of improving glucose and blood pressure control. Most individuals with type 2 diabetes and 5% to 30% of those with type 1 diabetes with progressive CKD have normal urine albumin excretion or low-level microalbuminuria (albumin-to-creatinine ratio approximately <100 mg/g), which does not progress despite the decline in glomerular filtration. People with progressive CKD but normal albuminuria have predominantly interstitial or vascular changes with much less glomerular changes. It seems likely that these histological abnormalities relate to blood pressure, aging, obesity, and intrarenal vascular disease. Initial studies suggested that 85% to 100% of diabetic individuals with microalbuminuria (Kidney Disease Improving Global Outcomes [KDIGO] CKD albuminuria A2) progressed to proteinuria (KDIGO CKD albuminuria A3). Recent data demonstrate that even after 2 to 3 years of persistent microalbuminuria, most will revert to normal albumin excretion (KDIGO CKD albuminuria A1). Regression is more likely at lower levels of microalbuminuria and with improved glucose, blood pressure, and lipid control. Thus, low levels of microalbuminuria cannot be considered as established diabetic nephropathy.
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CKD in diabetes; Diabetic nephropathy; Microalbuminuria/KDIGO CKD albuminuria A2; Natural history of diabetic nephropathy; Proteinuria/KDIGO CKD albuminuria A3

Mesh:

Year:  2014        PMID: 24780454     DOI: 10.1053/j.ackd.2014.03.007

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  20 in total

Review 1.  Genetics of diabetic nephropathy: a long road of discovery.

Authors:  Amy Jayne McKnight; Seamus Duffy; Alexander P Maxwell
Journal:  Curr Diab Rep       Date:  2015-07       Impact factor: 4.810

2.  Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus.

Authors:  Giuseppe Penno; Eleonora Russo; Monia Garofolo; Giuseppe Daniele; Daniela Lucchesi; Laura Giusti; Veronica Sancho Bornez; Cristina Bianchi; Angela Dardano; Roberto Miccoli; Stefano Del Prato
Journal:  Diabetologia       Date:  2017-03-29       Impact factor: 10.122

Review 3.  The genetic side of diabetic kidney disease: a review.

Authors:  Jinfang Song; Jiang Ni; Xiaoxing Yin
Journal:  Int Urol Nephrol       Date:  2022-08-16       Impact factor: 2.266

Review 4.  Early renal abnormalities as an indicator of cardiovascular risk in type 2 diabetes.

Authors:  Francesca Viazzi; Barbara Bonino; Elena Ratto; Salvatore De Cosmo; Roberto Pontremoli
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-08-01

5.  Cardiovascular autonomic neuropathy associates with nephropathy lesions in American Indians with type 2 diabetes.

Authors:  Kevin M Wheelock; Mamta Jaiswal; Catherine L Martin; Gudeta D Fufaa; E Jennifer Weil; Kevin V Lemley; Berne Yee; Eva Feldman; Frank C Brosius; William C Knowler; Robert G Nelson; Rodica Pop-Busui
Journal:  J Diabetes Complications       Date:  2016-03-11       Impact factor: 2.852

Review 6.  The Susceptibility Genes in Diabetic Nephropathy.

Authors:  Ling Wei; Ying Xiao; Li Li; Xiaofen Xiong; Yachun Han; Xuejing Zhu; Lin Sun
Journal:  Kidney Dis (Basel)       Date:  2018-09-06

Review 7.  The Role of Finerenone in the Management of Diabetic Nephropathy.

Authors:  Stavroula Veneti; Konstantinos Tziomalos
Journal:  Diabetes Ther       Date:  2021-05-29       Impact factor: 2.945

8.  Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CMS2728 at a single center.

Authors:  Christina M Yuan; Robert Nee; Kevin A Ceckowski; Kendral R Knight; Kevin C Abbott
Journal:  Clin Kidney J       Date:  2016-12-22

Review 9.  Revisiting Experimental Models of Diabetic Nephropathy.

Authors:  Anna Giralt-López; Mireia Molina-Van den Bosch; Ander Vergara; Clara García-Carro; Daniel Seron; Conxita Jacobs-Cachá; Maria José Soler
Journal:  Int J Mol Sci       Date:  2020-05-19       Impact factor: 5.923

10.  Targeted VEGF (Vascular Endothelial Growth Factor) Therapy Induces Long-Term Renal Recovery in Chronic Kidney Disease via Macrophage Polarization.

Authors:  Jason E Engel; Erika Williams; Maxx L Williams; Gene L Bidwell; Alejandro R Chade
Journal:  Hypertension       Date:  2019-09-23       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.